CDKN2A and mesothelioma: Inactivation of p16 appears to promote the pathogenesis of many tumor types, including mesothelioma, breast cancer, pancreatic cancer, non-small cell lung cancer, esophageal cancer, and head and neck cancer [14,15,16].